Active, Not Recruiting
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis - IM032-041
Aktualisiert:
24 Juni, 2024
|
ClinicalTrials.gov
Phase
Geschlecht(er)
Altersgruppe
Active, Not Recruiting
Inclusion Criteria: - Diagnosis of plaque psoriasis (PsO) for ≥ 6 months - Body mass index 18 to 40 kg/m^2 and total body weight > 50 kg (110 lbs) - Deemed by Investigator to be eligible for phototherapy or systemic therapy - Psoriatic plaques must cover ≥ 10% of body surface area at baseline - Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline Exclusion Criteria: - Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic) - Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment - Any significant acute or chronic medical illness Other protocol-defined inclusion/exclusion criteria apply
Wir empfehlen Ihnen dringend, sich an Bristol Myers Squibb zu wenden, um Nebenwirkungen (unerwünschte Ereignisse) zu melden.
Nebenwirkungen (unerwünschte Ereignisse) und andere meldepflichtige Ereignisse werden hier definiert
Nebenwirkungen (unerwünschte Ereignisse) oder Produktqualitätsbeschwerden melden: Medizinische Information